<unk> , sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma. Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness.<unk> , a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, is the third gene therapy approved by the U.S. Food and Drug Administration (FDA) for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL).<unk>  was approved for medical use in the United States in February 2021.
Lisocabtagene maraleucel
Ciltacabtagene autoleucel
Amylmetacresol
Palifermin
Idecabtagene vicleucel
Nicogel
Isavuconazonium
Ioxaglic acid